HealthEquity (HQY) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Revenue grew 18% year-over-year to $287.6 million in Q1 FY25, driven by record HSA sales, increased adoption of Enhanced Rates, and the BenefitWallet acquisition.
Adjusted EBITDA increased 36% to $117.4 million, with margin improving to 41% of revenue.
Net income rose to $28.8 million from $4.1 million, with non-GAAP net income at $73 million ($0.80/share).
BenefitWallet acquisition added up to 616,000 HSAs and $2.7 billion in assets, with the final tranche completed in May 2024.
Total accounts reached 16 million, including 9.1 million HSAs and $27.3 billion in HSA assets as of April 30, 2024.
Financial highlights
Service revenue was $118.2 million (+6% YoY), custodial revenue $121.6 million (+37%), and interchange revenue $47.7 million (+6%).
Gross profit increased to $187.1 million from $148.5 million, with margin improving to 65% from 61% YoY.
Net income per diluted share was $0.33 (GAAP) and $0.80 (non-GAAP), up from $0.05 and $0.50, respectively, in Q1 FY24.
Cash flow from operations was $65.4 million, up from $31.5 million in Q1 FY24.
Operating expenses rose 16% to $145.5 million, mainly due to higher stock-based compensation and personnel costs.
Outlook and guidance
FY25 revenue guidance raised to $1.16–$1.18 billion.
GAAP net income expected at $90–$105 million ($1.01–$1.18/share); non-GAAP net income at $261–$276 million ($2.93–$3.10/share).
Adjusted EBITDA forecasted at $454–$474 million.
Guidance incorporates BenefitWallet impact, higher net interest expense, and plans to pay down variable rate debt with operating cash flow.
Average HSA cash yield guidance increased to 3.00–3.05% for FY25.
Latest events from HealthEquity
- Revenue up 23%, net income up 239%, and $300M buyback announced for Q2 FY25.HQY
Q2 20259 Jul 2026 - Record FY25 revenue and HSA growth drive strong results and a positive FY26 outlook.HQY
Q4 20258 Jul 2026 - All proposals, including director elections and equity plans, were approved with no shareholder questions.HQY
AGM 202625 Jun 2026 - Net income up 29%, Adjusted EBITDA margin at 46%, and buybacks and guidance increased.HQY
Q1 20274 Jun 2026 - Board recommends all proposals amid strong financials and enhanced governance and ESG oversight.HQY
Proxy filing13 May 2026 - Key votes include board elections, auditor ratification, and approval of compensation and equity plans.HQY
Proxy filing13 May 2026 - Record HSA and revenue growth, margin expansion, and raised guidance signal strong momentum.HQY
Q4 202617 Mar 2026 - CEO transition to Scott Cutler set for January 2025, with strong growth and innovation focus.HQY
Investor Update14 Jan 2026 - Digital innovation, AI, and margin expansion fuel strong HSA growth and robust financial outlook.HQY
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026